Elevated Glucose Levels Favor Sars-Cov-2 Infection and Monocyte Response Through a Hif-1α/Glycolysis Dependent Axis

Autor: Raisa G. Ulaf, Pedro Vieira, Pierina Lorencini Parise, Helison Rafael Pereira do Carmo, Victor Corasolla Carregari, Lais D. Coimbra, Fabricio Pereira, Helder I. Nakaya, Fernanda Crunfli, Licio A. Velloso, A. F. Bernardes, Gustavo Gastão Davanzo, Jeffersson Leandro Jimenez Restrepo, Alexandre Borin, Vinícius O. Boldrini, Daniel Martins-de-Souza, Carlos Alberto Oliveira de Biagi, José Luiz Proença Modena, André Damasio, Maria Luiza Moretti, Marcus V. Agrela, Marcelo A. Mori, Andre C. Palma, Stéfanie Primon Muraro, Lauar de Brito Monteiro, Guilherme Reis-de-Oliveira, M. C. Martini, Andrei C. Sposito, Daniel Teixeira, Natalia S Brunetti, Robson Francisco Carvalho, Thyago A. Nunes, Pedro Henrique Vendramini, Alessandro S. Farias, Karina Rodrigues Santos, Marco Aurélio Ramirez Vinolo, André Schwambach Vieira, Ana Campos Codo, Gabriela F. P. de Souza, Eli Mansour
Rok vydání: 2020
Předmět:
Zdroj: SSRN Electronic Journal.
ISSN: 1556-5068
Popis: COVID-19 can result in severe lung injury. It remained to be determined why diabetic individuals with uncontrolled glucose levels are more prone to develop the severe form of COVID-19. The molecular mechanism underlying SARS-CoV-2 infection and what determines the onset of the cytokine storm found in severe COVID-19 patients are unknown. Monocytes/macrophages are the most enriched immune cell types in the lungs of COVID-19 patients and appear to have a central role in the pathogenicity of the disease. These cells adapt their metabolism upon infection and become highly glycolytic, which facilitates SARS-CoV-2 replication. The infection triggers mitochondrial ROS production, which induces stabilization of hypoxia-inducible factor- 1α (HIF - 1α) and consequently promotes glycolysis. HIF- 1α-induced changes in monocyte metabolism by SARS-CoV-2 infection directly inhibit T cell response and reduce epithelial cell survival. Targeting HIF-1 ɑ may have great therapeutic potential for the development of novel drugs to treat COVID-19.
Databáze: OpenAIRE